Elena Poddubskaya

机构：Sechenov University · ORCID：0000-0001-6476-6337

发表论文 119 篇 · 总被引 22813 次 · h-index 31

代表论文

• Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial (2024 · BMJ · 被引 266)
• Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study (2024 · Journal of Clinical Oncology · 被引 211)
• RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 37)
• Role of ERK1/2 and p38 Protein Kinases in Tumors: Biological Insights and Clinical Implications (2025 · Frontiers in Bioscience-Landmark · 被引 8)
• Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients (2024 · Frontiers in Immunology · 被引 6)
• OA08.03 Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01 (2024 · Journal of Thoracic Oncology · 被引 5)